

Phenotypic detection of extended spectrum beta-lactamases (ESBLs) in Gram-negative bacilli isolated from deferent clinical source

Sajid Abdelsada Sahel¹

Department of Pathological Analysis,
College of Science, University of Thi-
Qar/Refaie – Iraq

Email: sajidlion@sci.utq.edu.iq

Intidhaar Naeem Abid²

Department of Pathological Analysis,
College of Science, University of Thi-
Qar Nasiriyah – Iraq
Email: Intidhaar12ih_pa@sci.utq.edu.iq

Abstract— This study aimed to the detection of extended spectrum beta-lactamases by phenotypic and genotypic methods in nosocomial Gram-negative isolates. A number of 194 samples from hospitalized patients (urine, burn swab, surgical swab, and sputum) were collected. These patients were at Al-Hussein and Al-Nasiriyah teaching hospitals in Al-Nasiriyah city. ESBLs enzymes were detected phenotypically by ceftazidime (30 µg) and cefotaxime (30 µg) (Screening test) and Double Disk Synergy Test (DDST) (Confirming test). The results showed that out of 109 isolates 89 (81.65%) were Gram negative bacilli. A total of 68 Gram-negative were β -lactamases producer. Moreover, the results of screening test recorded that 55 (80.88%) of isolates were resistant to cefotaxime and ceftazidime, while 17 (25%) isolates produced ESBLs by (DDST).

Keywords— Extended-spectrum β -lactamases, Gram-negative bacilli, DDST

I. Introduction

Most β -lactam antibiotics, including cephalosporins, penicillins, aztreonam, and related oxymimino β -lactams, can be hydrolyzed by extended-spectrum β -lactamases, with the exception of cephamycins (cefoxitin) and carbapenems, which can only be blocked by β -lactamase inhibitors such as clavulanic acid⁽¹⁾. (ESBLs) have been found in almost Gram-negative bacteria, especially Enterobacteriaceae and *P. aeruginosa*⁽²⁾. These enzymes include members of the TEM, SHV, CTX-M, and OXA enzyme families⁽³⁾. The property of ESBLs, which are active site serine Ambler's class A or class D β -lactamases, to hydrolyze and produce resistance to third- and fourth-generation cephalosporins and monobactams, is one of their distinguishing features⁽⁴⁾.

In the recent two decades, numerous substantial alterations in ESBL-producing isolates have been observed globally. ESBL producers have emerged as an important multidrug-resistant pathogen⁽⁵⁾. Since these compounds were identified in the early 1980s, they have become prevalent in Enterobacteriaceae isolated from both hospital-associated illnesses and community-acquired infections⁽⁶⁾. The most often implicated pathogens in large nosocomial outbreaks produced by ESBL-producing Gram-negative bacilli are *E. coli* and *K. pneumoniae*⁽⁷⁾. The ESBL enzyme

genes are often present in plasmids. They also are available in chromosomal DNA⁽⁸⁾.

II. MATERIALS AND METHODS

Collection of Samples

Between December 2021 and March 2022, a total of 194 samples were collected from hospitalized patients (including urinary tract 75, surgical wound 52, sputum from respiratory tract 40 and burn swabs 27). These samples were taken from patients at Al-Hussein and Al-Nasiriyah teaching hospitals. All samples were transported to the laboratory and inoculated on blood agar and MacConkey agar and incubated at 37 °C for 24 to 48 hr. The identification of bacteria was dependent on the morphological examination, microscopic examination, biochemical tests and confirmed by API 20 E system and VITEK-2 system.

Detection of β -lactamase production

All isolates were tested for their ability to the production of β -lactamases by Rapid iodometric method according to Miles *et al.*, 1994⁽⁹⁾.

phenotypic methods for detection Extended-spectrum β -lactamases (ESBLs) production

1-Screening test of ESBLs

To screen all isolates for the production of ESBL enzymes, two discs were placed on Muller Hinton Agar with the test bacterium were ceftazidime (30 µg) and cefotaxime (30 µg) at a distance of 30 mm (center to center) and incubation at 37°C for 24hr according to the CLSI guidelines⁽¹⁰⁾, if the diameter of inhibition zone around ceftazidime is ≤ 22 mm or Cefotaxime zone ≤ 27 mm it was considered positive.

2-Confirmation of ESBL production

In this part of the present study, ESBLs production was confirmed by Double Disk Synergy Test (DDST). On Muller Hinton Agar with suspended bacteria was incubated

with cefepime (30 µg), aztreonam (30 µg), ceftazidime (30 µg), cefotaxime (30 µg), and ceftriaxone (30 µg) alone with Augmentin (amoxicillin 20 µg, clavulanate acid 10 µg) at the center and 30 mm apart (center to center) on an inoculated agar plate. A clear extension of the edge of the cephalosporins disk inhibition zone toward the disk containing clavulanate was interpreted as synergy, indicating the presence of an ESBL⁽¹¹⁾.

III. RESULTS

Out of 194 hospitalized patients, 109 bacterial isolates were recorded as positive cultures with a percentage of 56.19%, urinary tract specimens registered a high number of positive cultures was recorded, it was 47 (43.12%). The results appeared that the burn swabs were the lower specimens that gave positive culture 11 (10.09%). With the remaining 85 with a percentage 43.81% being negative growth, 75 (38.66%) of samples were collected from the Urinary tract, 52 (26.80%) from the surgical wound, 40 (20.62%) respiratory tract and 27 (13.92%) burn swabs.as shown in Table 1.

Urinary tract infections were the most frequent source of the isolated Gram-negative bacteria (38 (42.70%)), followed by surgical wounds (23 (25.84%)), respiratory tract (19 (21.35%)), and 9 (10.11%) of burn swabs, out of the 109 positive cultures from hospitalized patients, the results found that Gram-positive bacteria registered 20 (18.35%)) isolates identified from nosocomial infection (SEE table 2).

Total of 89 isolates of Gram-negative bacilli were tested for their ability to the β -lactamase enzyme by the rapid iodometric method. The results showed that 68 of isolates revealed positive results of β -lactamase production. *E. coli* recorded the high percentage 26 (38.24%) following by *K. pneumoniae* 17 (25.00%) as demonstrated in Table 3.

Production of Extended Spectrum lactamases (ESBL)

The ESBL initial screen disk test was assessed using cefotaxime and ceftazidime disks. A number of 68 isolates of Gram negative were screened and verified for ESBL production. The results of the study showed that 55 (80.88%) of isolates were resistant to cefotaxime and ceftazidime and ESBL positive during the initial screening and 17 (25%) isolates producing ESBLs, with confirmatory test (DDST).(Table 4).

Table 4: Numbers and percentages of ESBLs producing Gram-negative bacterial isolates by phenotypic tests.

Source of sample	Bacteria	No. β -lactamase producer isolates	No. and (%) Suspected ESBL of producing Gram-negative isolates			
			Screening test		Confirmatory test	
			positive results	negative results	Positive results	Negative results
Hospitalized patients	<i>E. coli</i>	26	21 (38.18)	5 (38.46)	8 (47.06)	18 (35.29)
	<i>K. pneumoniae</i>	17	13 (23.64)	4 (30.77)	5 (29.41)	12 (23.53)
	<i>P. aeruginosa</i>	15	12 (21.82)	3 (23.08)	3 (17.65)	12 (23.53)
	<i>E. cloacae</i>	5	4 (7.27)	1 (7.69)	0 (0.00)	5 (9.80)
	<i>A. baumannii</i>	5	5 (9.09)	0 (0.00)	1 (5.88)	4 (7.84)
Total		68	55 (80.88)	13(19.12)	17(25.00)	58(75.00)

Table 1: Numbers and percentages of nosocomial infections (IN) from

different sites of hospitalized patients.

Site of NI	No. & (%) positive culture	No. & (%) negative culture	Total & (%)
Urinary tract	47 (43.12)	28 (32.94)	75 (38.66)
Surgical wound	28 (25.69)	24 (28.24)	52 (26.80)
Respiratory tract	23 (21.10)	17 (20.00)	40 (20.62)
Burn swabs	11 (10.09)	16 (18.82)	27 (13.92)
Total	109 (56.19)	85 (43.81)	194 (100.00)

Table 2: Numbers and percentages of Gram negative bacteria isolated from nosocomial infections.

Site of NI	No. and (%) of Gram-negative isolates	No. and (%) of Gram-positive isolates	Total
Urinary tract	38 (42.70)	9 (45.00)	47 (43.12)
Surgical wound	23 (25.84)	5 (25.00)	28 (25.69)
Respiratory tract	19 (21.35)	4 (20.00)	23 (21.10)
Burn swabs	9 (10.11)	2 (10.00)	11 (10.09)
Total	89 (81.65)	20 (18.35)	109 (100.00)

Table 3: Number and percentage of β -lactamase producing Gram-negative bacterial isolates by the rapid iodometric method.

Gram-negative bacilli	No. of isolates	No. and (%) of β -lactamase producing isolates
<i>E. coli</i>	35	26 (38.24)
<i>K. pneumoniae</i>	24	17 (25.00)
<i>P. aeruginosa</i>	19	15 (22.06)
<i>A. baumannii</i>	6	5 (7.35)
<i>E. cloacae</i>	5	5 (7.35)
Total	89	68

IV. Discussion

The results showed that, out of 68 β -lactamases 55 (80.88%) were ceftazidime and cefotaxime resistant. This high percentage of ESBLs producers agrees with the results of a study performed in India by Rajivgandhi *et al.* (2018)⁽¹²⁾ were showed that (84%) of Gram-negative bacterial isolates from clinical specimens against cefotaxime and ceftazidime were potentially positive. This may be too extensive used for broad-spectrum antibiotics and to a higher level in the community setting, combined with a disregard for laboratory testing of clinical isolates' development of ESBL⁽¹³⁾.

Moreover, the results of the present study illustrated that the isolates were *E. coli* isolates are significantly more frequently for ESBL-producing strains by both phenotypic methods screening and confirmatory tests. In particular beyond the confines of a clearly defined epidemic, the mechanisms of transmission and dissemination of ESBL- *E. coli* in hospital settings are not entirely known. Although it has traditionally been thought of as the most likely mechanism of transmission⁽¹⁴⁾. This percentage agrees with the results of a study from Saudi Arabia by Kader and Angamuthu, (2005)⁽¹⁵⁾ and with the Chinese study of Wang *et al.* (2003)⁽¹⁶⁾. In *Klebsiella* spp isolates, ESBL production was found in 23.64%. These results are in agreement with the Egyptian study of Ahmed *et al.* (2013)⁽¹⁷⁾ that demonstrated that the ESBL rate in *Klebsiella pneumoniae* was 21% which isolated from hospitalized patients.

In the present study, the results revealed that 25% of Gram-negative isolates were ESBLs producers by DDST. These results are similar to the results of the study of nosocomial Gram-negative bacilli isolates by Singh *et al.* (2012)⁽¹⁸⁾ and Mshana, (2009)⁽¹⁹⁾ who found ESBLs producer was 27% and 29%, respectively. These results were lower than the results conducted by Saha *et al.* (2017)⁽²⁰⁾ were registered 41.40% of the Gram-negative bacilli isolated from nosocomial infections. The use of clavulanic acid to inhibit an ESBL may induce high level expression of the chromosomal AmpC enzyme and may then antagonize rather than protect the antibacterial activity of the partner lactam, preventing the synergistic effect required to detect ESBL production, which may explain the lower percentage in this method⁽²¹⁾.

In concluded Gram-negative bacteria were the most pathogens causing nosocomial infections. *E. coli* and *K. pneumoniae* were the majority of Gram-negative isolates that infected hospitalized patients. *E. coli* and *K. pneumoniae* were the most isolates producing ESBLs.

ACKNOWLEDGEMENT

We would express a special thanks and gratitude to the staff of laboratories of Al-Hussein and Al-Nasiriyah teaching hospitals and private laboratories for their great help.

REFERENCES

1. Gebremichael S, Id T, Shiferaw Teklu D, Tullu KD, Kinde Birru S, Legese MH. Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia. 2020; Available from: <https://doi.org/10.1371/journal.pone.0241984>
2. Fanaei V, Validi M, Zamanzad B, Karimi A. Isolation and identification of specific bacteriophages against methicillin-resistant *Staphylococcus aureus*, extended-spectrum beta-lactamases-producing *Escherichia coli*, extended-spectrum beta-lactamases-producing *Klebsiella pneumoniae*, and multidrug-resistant *Acinetobacter baumannii* in vitro. FEMS Microbiol Lett. 2021;368(19):1–6.
3. C Reygaert W. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4(3):482–501.
4. Hamadamin HA, Baban STH, Hussien BM, Ali FA. Distribution of bla TEM Gene among *Escherichia coli* Strains Isolated from Different Clinical Samples in Erbil City Abstract: Introduction: 2019;(January).
5. Shilpakar A, Ansari M, Rai KR, Rai G, Rai SK. Prevalence of multidrug-resistant and extended-spectrum beta-lactamase producing Gram-negative isolates from clinical samples in a tertiary care hospital of Nepal. Trop Med Health. 2021;49(1).
6. Castanheira M, Simner PJ, Bradford PA. Extended-spectrum β -lactamases: an update on their characteristics, epidemiology and detection . JAC-Antimicrobial Resist [Internet]. 2021;3(3). Available from: <https://www.ncbi.nlm.nih.gov/pathogens/isolates#/refgene/TEM;>
7. Manzur A, Tubau F, Pujol M, Calatayud L, Dominguez MA, Peña C, et al. Nosocomial Outbreak Due to Extended-Spectrum-Beta-Lactamase- Producing *Enterobacter cloacae* in a Cardiothoracic Intensive Care Unit. J Clin Microbiol [Internet]. 2007 Aug [cited 2022 Jun 29];45(8):2365. Available from: [/pmc/articles/PMC1951272/](https://pubmed.ncbi.nlm.nih.gov/1951272/)
8. Guiral E, Pons MJ, Vubil D, Marí-Almirall M, Sigaúque B, Soto SM, et al. Epidemiology and molecular characterization of multidrug-resistant *Escherichia coli* isolates harboring blaCTX-M group 1 extended-spectrum β -lactamases causing bacteremia and urinary tract infection in Manhiça, Mozambique. Infect Drug Resist [Internet]. 2018;11:927–36. Available from: <http://dx.doi.org/10.2147/IDR.S153601>
9. Hekma Mohammed Salih Al-Sudani1* &Amani Mohammed Ali Jameel. Emergence of Extended Spectrum β - Lactamases (ESBL) In Clinical Isolates of *Klebsiella pneumoniae* In Rada'a Tamar Cities, Yemen. Albaydha Univ J. 2020;2(2):91–108.
10. CLSI. CLSI M100-ED29: 2021 Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition. Vol. 40, Clsi. 2020. 50–51 p.

11. Thomson KS. Detection of Gram-negative β -lactamase producing pathogens in the Clinical Lab. *Curr Pharm Des*. 2013;19(2):250–6.
12. Rajivgandhi G, Maruthupandy M, Ramachandran G, Priyanga M, Manoharan N. Detection of ESBL genes from ciprofloxacin resistant Gram negative bacteria isolated from urinary tract infections (UTIs). *Front Lab Med* [Internet]. 2018;2(1):5–13. Available from: <https://doi.org/10.1016/j.flm.2018.01.001>
13. Al-Ouqaili MT, Al-Kubaisy SH, Al-Ani AJ. Detection of extended spectrum and ambler class C beta-lactamases among beta-lactam resistant *Klebsiella* species: Genetic aspects. *Egypt J Exp Biol*. 2011;7:299–308.
14. Adler A, Gniadkowski M, Baraniak A, Izdebski R, Fiett J, Hryniewicz W, et al. Transmission dynamics of ESBL-producing *Escherichia coli* clones in rehabilitation wards at a tertiary care centre. *Clin Microbiol Infect* [Internet]. 2012;18(12):E497–505. Available from: <http://dx.doi.org/10.1111/j.1469-0691.2012.03999.x>
15. Kader AA, Angamuthu K. Extended-spectrum beta-lactamases in urinary isolates of *Escherichia coli*, *Klebsiella pneumoniae* and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia. *Saudi Med J*. 2005;26(6):956–9.
16. Wang H, Kelkar S, Wu W, Chen M, Quinn JP. Clinical isolates of Enterobacteriaceae producing extended-spectrum β -lactamases: Prevalence of CTX-M-3 at a hospital in China. *Antimicrob Agents Chemother*. 2003;47(2):790–3.
17. Ahmed OI, El-Hady SA, Ahmed TM, Ahmed IZ. Detection of bla SHV and bla CTX-M genes in ESBL producing *Klebsiella pneumoniae* isolated from Egyptian patients with suspected nosocomial infections. *Egypt J Med Hum Genet* [Internet]. 2013;14(3):277–83. Available from: <http://dx.doi.org/10.1016/j.ejmhg.2013.05.002>
18. Manojkumar Singh RK, Pal NK, Banerjee M, Sarkar S, SenGupta M. Surveillance on extended spectrum β -lactamase and AmpC β -lactamase producing gram negative isolates from nosocomial infections. *Arch Clin Microbiol*. 2012;3(3):0.
19. Mshana S. State of the globe: Evaluating the existence of extended spectrum beta lactamases. *J Glob Infect Dis*. 2009;1(2):85.
20. Saha MR, Jhora ST, Khan TM, Paul S, Chowdhury D. Detection of SHV Gene from Extended-Spectrum Beta-Lactamases (ESBLs) Producing Isolates in a Tertiary Care Hospital. *Bangladesh J Med Microbiol*. 2017;8(2):14–8.
21. Apfalter P, Assadian O, Daxböck F, Hirschl AM, Rotter ML, Makristathis A. Extended double disc synergy testing reveals a low prevalence of extended-spectrum β -lactamases in *Enterobacter* spp. in Vienna, Austria. *J Antimicrob Chemother*. 2007;59(5):854–9.